Tocilizumab and anti-tumour necrosis factor as first biologic agents in patients with rheumatoid arthritis. Efficacy data from the Rheumatic Diseases Portuguese Register.

Trial Profile

Tocilizumab and anti-tumour necrosis factor as first biologic agents in patients with rheumatoid arthritis. Efficacy data from the Rheumatic Diseases Portuguese Register.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2015

At a glance

  • Drugs Anti-TNF monoclonal antibodies (Primary) ; Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top